Patents by Inventor Fred Windt
Fred Windt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20070243240Abstract: The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy.Type: ApplicationFiled: March 24, 2005Publication date: October 18, 2007Inventors: Fred Windt-Hanke, Clemens Gunther, Reinhard Horowski, Johannes Tack, Adalbert Engfer, Katalin Bostedt, Dirk Schenk
-
Publication number: 20060105030Abstract: The invention concerns a transdermal therapeutic system containing ergoline derivatives, preferably lisuride, with a stabilized ergoline compound. Stabilization of the oxidation sensitive ergoline combination is done through a combination of at least one fat-soluble, radical-trapping antioxidant, preferably Di-tert.-butylmethylphenols, Di-tert.-butylmetoxyphenols, tocopherols or ubichinones and a basic polymer. Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy.Type: ApplicationFiled: March 24, 2005Publication date: May 18, 2006Inventors: Fred Windt-Hanke, Clemens Gunther, Reinhard Horowski, Johannes Tack, Adalbert Engfer, Katalin Bostedt, Dirk Schenk
-
Publication number: 20050220855Abstract: Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the restless-legs-syndrome.Type: ApplicationFiled: April 28, 2005Publication date: October 6, 2005Inventors: Reinhard Horowski, Johannes Tack, Fred Windt-Hanke, Clemens Gunther, Adalbert Engfer, Katalin Bostedt, Dirk Schenk
-
Publication number: 20050214353Abstract: Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy. The invention relates to the use of a transdermal therapeutic system (TTS) comprising a medicinal layer, which contains at least one matrix comprising an active ingredient and/or an active ingredient reservoir and a diffusion barrier situated on the skin side of the active ingredient reservoir and permeable to active ingredients, in addition to, an ergoline-derivative or physiologically compatible salt with an acid thereof, as an active ingredient, for producing a means for treating the restless-legs-syndrome.Type: ApplicationFiled: April 28, 2005Publication date: September 29, 2005Inventors: Reinhard Horowski, Johannes Tack, Fred Windt-Hanke, Clemens Gunther, Adalbert Engfer
-
Publication number: 20040101550Abstract: Use of a transdermal therapeutic system (TTS) comprising a pharmaceutical layer containing at least one matrix having an active ingredient and/or an active ingredient reservoir; a diffusion barrier that is permeable to said active ingredient and arranged on the skin side of the active ingredient reservoir; and an ergoline derivative or salt thereof as an active ingredient for producing an agent for obtaining and maintaining the circadian rhythm under dopamine therapy.Type: ApplicationFiled: July 7, 2003Publication date: May 27, 2004Inventors: Fred Windt-Hanke, Clemens Gunther, Reinhard Horowski, Johannes Tack
-
Publication number: 20040081682Abstract: The invention relates to a transdermal system that is characterized by a content in a phosphodiesterase IV inhibitor, especially (−) rolipram or (R)-(−)-5-(4-methoxyphenyl-3-propoxy)-5-methyl-2-oxazolidinone.Type: ApplicationFiled: November 26, 2003Publication date: April 29, 2004Inventors: Clemes Guenther, Ralph Lipp, Fred Windt
-
Patent number: 5286494Abstract: Medicinal agents are claimed exhibiting sustained release of active compound, containing a solid active ingredient, poorly soluble in water, and auxiliary agents, characterized in that the active compound, in a microcrystalline form or in form of a molecular dispersion, is distributed in or on pellets, and that the pellets are covered by a membrane having retarded permeability with respect to the active compound.Type: GrantFiled: June 17, 1991Date of Patent: February 15, 1994Assignee: Schering AktiengesellschaftInventors: Christian Fechner, Michael Humpel, Fred Windt-Hanke, Johannes Tack
-
Patent number: 5071657Abstract: A device for transdermal administration of active medicinal agents is based on the active medicinal agent dissolved to an extent of at least 50% in a nonflowable, physiologically acceptable gel, which latter is distributed in a microdisperse mode in a crosslinked silicone elastomer.Type: GrantFiled: August 31, 1990Date of Patent: December 10, 1991Assignee: Schering AktiengesellschaftInventors: Horst Oloff, Johannes-Wilhelm Tack, Fred Windt, Ingfried Zimmermann
-
Patent number: 4822616Abstract: A vaginal ring comprises a supporting ring 1 free of active agent. A layer 2, which contains an active agent such as a steroid, is applied on its outer rim, optionally in a continuous groove provided in the supporting ring. This layer, in turn, is coated with a layer 3 devoid of active ingredient. All components preferably comprise an LTV silicone elastomer. The ratio of the thickness of the layer 2, containing an active agent, to the layer 3, free of active agent, is about 5-50:1. As a result, a long-term and uniform release rate is achieved for the active agent.Type: GrantFiled: February 13, 1987Date of Patent: April 18, 1989Assignee: Schering AktiengesellschaftInventors: Ingfried Zimmermann, Fred Windt, Hans-Jurgen Reck
-
Patent number: 4814175Abstract: The invention relates to nifedipine combination preparations, containing nifedipine with delayed release of active agent and a .beta.-blocker in each case in granulated form, and their pharmaceutical usage as a therapeutic agent in cardiovascular diseases.Type: GrantFiled: November 23, 1987Date of Patent: March 21, 1989Assignee: Schering AktiengesellschaftInventors: Johannes-Wilhelm Tack, Manfred Albring, Fred Windt-Hanke
-
Patent number: 4155991Abstract: A composite vaginal ring containing a safe and effective amount of a pharmaceutically active medicament, which comprises:(a) a major supporting vaginal ring consisting essentially of a physiologically acceptable synthetic resin and having at least a portion of the annular surface thereof adapted to mate with corresponding minor, medicament-containing vaginal ring segment; and(b) at least one minor, medicament-containing vaginal ring segment adapted to mate with the modified annular surface of said major supporting vaginal ring and consisting essentially of a safe and effective amount of a pharmaceutically active amount of a nonionic, lipophilic drug dissolved or uniformly suspended in an elastomeric, cross-linked LTV linear dimethylpolysiloxane resin.Type: GrantFiled: March 3, 1977Date of Patent: May 22, 1979Assignee: Schering AktiengesellschaftInventors: Gisela Schopflin, Gerhard Laudahn, Barbara Muhe, Heidemarie Hartmann, Fred Windt
-
Patent number: 4012496Abstract: A composite vaginal ring containing a safe and effective amount of a pharmaceutically active medicament, which comprises:A. a major supporting vaginal ring consisting essentially of a physiologically acceptable synthetic resin and having at least a portion of the annular surface thereof adapted to mate with corresponding minor, medicament-containing vaginal ring segment; andB. at least one minor, medicament-containing vaginal ring segment adapted to mate with the modified annular surface of said major supporting vaginal ring and consisting essentially of a safe and effective amount of a pharmaceutically active amount of a nonionic, lipophilic drug dissolved or uniformly suspended in an elastomeric, cross-linked LTV linear dimethylpolysiloxane resin.Type: GrantFiled: October 17, 1975Date of Patent: March 15, 1977Assignee: Schering AktiengesellschaftInventors: Gisela Schopflin, Gerhard Laudahn, Barbara Muhe, Heidemarie Hartmann, Fred Windt